1093 (1093) News
Follow 1093 (1093) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
L
CSPC Pharmaceutical Initiates Phase IB Clinical Trial Of JMT206 Injection In China
CSPC PHARMACEUTICAL GROUP LIMITED HKEX:1093
GEOPOLITICS | Sep 29, 2026, 10:21 AM UTC
L
Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval In U.S.
CSPC PHARMACEUTICAL GROUP LIMITED HKEX:1093
REGULATION | Sep 29, 2026, 10:07 AM UTC
L
Cspc Pharmaceutical's Sys6077 Injection Obtains Clinical Trial Approval In China
CSPC PHARMACEUTICAL GROUP LIMITED HKEX:1093
GEOPOLITICS | Sep 28, 2026, 10:17 AM UTC
L
CSPC Pharmaceutical Says Phase III Trial Of Becotatug Achieves Positive Topline Results
CSPC PHARMACEUTICAL GROUP LIMITED HKEX:1093
NEWS | Sep 24, 2026, 03:02 PM UTC
L
CSPC Pharmaceutical Initiates Phase III Trial Of HB1801 For Advanced Breast Cancer In China
CSPC PHARMACEUTICAL GROUP LIMITED HKEX:1093
GEOPOLITICS | Sep 24, 2026, 09:04 AM UTC
L
Cspc Pharmaceutical Says SYS6010 Granted Breakthrough Therapy Designation By NMPA
CSPC PHARMACEUTICAL HKEX:1093
NEWS | Sep 15, 2026, 10:17 AM UTC
L
CSPC Pharma's Clinical Data Presentations Could Be Near-Term Share Catalysts — Market Talk
CSPC Pharmaceutical's coming clinical data presentations over the next two months could serve as near-term share-price catalysts, say DBS Group Research's Mark Kong and Nico Chen in a note. The Chinese pharmaceutical gro
EQUITY | Sep 10, 2026, 06:08 AM UTC
L
DBS Group Research resumes Buy on 1093.HK CSPC Pharmaceutical
EQUITY | Sep 10, 2026, 05:48 AM UTC
L
CSPC Pharmaceutical’s rotigotine long-acting injection wins China clinical approval
CSPC Pharmaceutical Group said its rotigotine long-acting injection received clinical trial approval in China.
GEOPOLITICS | Sep 09, 2026, 10:34 AM UTC
M
CSPC Pharmaceutical’s goserelin sustained-release injection approved for China trial
CSPC Pharmaceutical Group says its goserelin sustained-release injection has received clinical trial approval in China.
GEOPOLITICS | Sep 09, 2026, 10:33 AM UTC
M
CSPC Pharmaceutical wins China approval for SYH2083 eye drops
CSPC Pharmaceutical Group says SYH2083 eye drops have obtained clinical trial approval in China, per TradingView News.
GEOPOLITICS | Sep 08, 2026, 10:34 AM UTC
L
CSPC Pharmaceutical starts Phase I trial for SYH2056 tablets in China
CSPC Pharmaceutical Group Limited has initiated a Phase I clinical trial in China of SYH2056 tablets.
GEOPOLITICS | Sep 01, 2026, 03:56 PM UTC
L
CSPC Pharmaceutical’s SYS6010 gets Breakthrough Therapy designation
CSPC Pharmaceutical said SYS6010 was granted Breakthrough Therapy designation by the NMPA.
EQUITY | Sep 01, 2026, 10:31 AM UTC
L
CSPC Pharmaceutical starts Phase I trial of SYH2092 injection
CSPC Pharmaceutical has initiated a Phase I clinical trial of SYH2092 injection.
EQUITY | Aug 31, 2026, 03:29 PM UTC